DRTS Stock Forecast & Price Target

Alpha Tau Medical Ltd has recently achieved a significant operational milestone by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, enabling the company to initiate commercial-scale manufacturing of its Alpha DaRT technology, with production expected to start in 2026. This development reflects the company's positive trajectory in addressing a critical unmet need in the oncology market through its innovative approach to localized radiation therapy. Furthermore, Alpha Tau maintains a strong cash position, which could support its ongoing operational activities and future growth potential despite reporting a net loss of $11.7 million for the recent period.

Alpha Tau Medical reported a net loss of $11.7 million in 3Q25, highlighting ongoing financial challenges as the company remains in its clinical development phase. The company faces significant risks, including potential failures in clinical trials, challenges in securing regulatory approvals in the U.S., and difficulties in achieving commercial success amid competitive pressures and market constraints. Additionally, the risk of dilution further complicates the financial outlook, raising concerns among investors about the viability and sustainability of future funding.